Stock Events

Stock Events

Microba Life Sciences 

€0.04
0
+€0+4.11% Wednesday 06:04

Statistics

Day High
0.04
Day Low
0.04
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
23.14M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q4 2024
Q2 2025
Q4 2025
-0.01
-0.01
-0.01
-0.01
Expected EPS
-0.005647870899999999
Actual EPS
-0.01016616762

Financials

-94.9%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
17.81MRevenue
-16.9MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow F3Y.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap19.43B
Illumina provides genomic sequencing solutions and competes in the microbiome analysis space, similar to Microba's core services.
Pacific Biosciences of California
PACB
Mkt Cap484.36M
Pacific Biosciences offers long-read sequencing technologies that can be used for microbiome research, competing with Microba's sequencing services.
Thermo Fisher Scientific
TMO
Mkt Cap174.55B
Thermo Fisher Scientific offers a range of life sciences solutions including microbiome research tools, directly competing with Microba.
Qiagen NV
QGEN
Mkt Cap7.92B
Qiagen provides sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, overlapping with Microba's market.
Bio-Rad Laboratories
BIO
Mkt Cap7.77B
Bio-Rad Laboratories manufactures and supplies products and systems used for genetic research, which includes microbiome studies.
Guardant Health
GH
Mkt Cap11.66B
Guardant Health focuses on cancer diagnostics but also explores genomic sequencing for other applications, potentially competing in the microbiome space.
Repligen
RGEN
Mkt Cap6.67B
Repligen offers bioprocessing technologies and solutions, which are crucial for microbiome research and development, similar to Microba's offerings.
Quest Diagnostics
DGX
Mkt Cap21.73B
Quest Diagnostics provides diagnostic information services, including genetic testing and analysis, which can overlap with microbiome testing.
Fulgent Genetics
FLGT
Mkt Cap470.46M
Fulgent Genetics offers comprehensive genetic testing, which can include microbiome analysis, thus competing with Microba's services.

About

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
Show more...
CEO
Dr. Luke Reid
Country
Germany
ISIN
AU0000209868
WKN
000A3DE79

Listings

F
DE
F3Y.F
AU
AU
MAP.AU

0 Comments

Share your thoughts

FAQ

What is Microba Life Sciences stock price today?▼
The current price of F3Y.F is €0.04 EUR — it has increased by +4.11% in the past 24 hours. Watch Microba Life Sciences stock price performance more closely on the chart.
What is Microba Life Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Microba Life Sciences stocks are traded under the ticker F3Y.F.
What is Microba Life Sciences market cap?▼
Today Microba Life Sciences has the market capitalization of 23.14M
When is the next Microba Life Sciences earnings date?▼
Microba Life Sciences is going to release the next earnings report on September 01, 2026.
What were Microba Life Sciences earnings last quarter?▼
F3Y.F earnings for the last quarter are -0.01 EUR per share, whereas the estimation was -0.01 EUR resulting in a -80% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Microba Life Sciences revenue for the last year?▼
Microba Life Sciences revenue for the last year amounts to 17.81M EUR.
What is Microba Life Sciences net income for the last year?▼
F3Y.F net income for the last year is -16.9M EUR.
In which sector is Microba Life Sciences located?▼
Microba Life Sciences operates in the Other sector.
When did Microba Life Sciences complete a stock split?▼
Microba Life Sciences has not had any recent stock splits.
Where is Microba Life Sciences headquartered?▼
Microba Life Sciences is headquartered in Brisbane, Germany.